


A Global Patient Perspective on the

Burden of Living with axSpA

Created with the patient and medical community around the world



Following first onset of symptoms, participants around the world waited on average



waited two years longer than men to be diagnosed¹

On average, women



Average diagnostic


Diagnostic delay in axSpA can greatly impact spinal mobility


Participants who experienced longer diagnostic delays were more likely to suffer from greater spinal stiffness²



Spinal Stiffness Index	No restriction	3.7
	Mild	5.4
	Moderate	7.5
	Severe	9.1

sub-optimally controlled disease:





Average participant BASDAI score:

controlled disease.

Comorbidities are common in axSpA

Participants with higher reported disease activity reported an average of **2.4**

comorbidities, compared to **1.4** reported by those with low disease activity²

Participants reported²...

axSpA can place a significant psychological toll on people living with the disease

Sleep disorders: 43.4%




Anxiety: **40.5%**



Depression: 37.2%







Despite this, only



axSpA can have a considerable impact on

70.6% **70.7**% **68.4**% had trouble getting struggled with dressing found going down

almost EVERY PART of a person's life

Respondents reported some functional limitation in a range of daily activities²

73.2% 63.3% 50.5%



housework

out of bed

had trouble with shopping

and undressing

struggled with going to the toilet

the stairs difficult

axSpA can have a significant impact on CAREER PROSPECTS

Work colleagues

45.1%

31.3% Spouse / partner

Participants with sub-optimally controlled disease (BASDAI ≥ 4) had a higher

35.1%

Friends

Family

71.4%

reported difficulty finding a job due to their disease²

45.7%

reported that their job choice was influenced by their disease²

Average number of visits in

axSpA can have a considerable impact on healthcare resource utilisation

the prior 12 months BASDAI < 4 BASDAI ≥ 4 Physiotherapist 8.0 13.7 Primary care 2.7 5.2 physician

number of healthcare visits²

1. Poddubnyy D, Garrido-Cumbrera M, Sommerfleck F, et al. POS0689. Diagnostic delay in patients included in the International Map of Axial Spondyloarthritis: associations with geographic,

socio-demographic and disease-related factors. Annals of the Rheumatic Diseases. 2023;82:628-629 2. The burden of axial spondyloarthritis: A global patient perspective. International Map of Axial Spondyloarthritis (IMAS) Report. January 2024. https://asif.info/imas/jmas-global-report 3. Poddubnyy D, Sommerfleck F, Navarro-Compán V, et al. OP0187. Regional differences in clinical phenotype of axial spondyloarthritis. Results from the International Map of Axial Spondyloarthritis

Developed through a collaboration between Novartis Pharma AG and the Axial Spondyloarthritis International Federation (ASIF).



Date of preparation: January 2024



MLR ID 319016